Blog dermatologico

Elenco degli articoli con argomento «ustekinumab»

Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab

Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti–Interleukin 12/23p40 Antibody Ustekinumab

Ricerca

Is the risk of severe cardiovascular events increased after the initiation of treatment with the anti–interleukin 12/23p40 (IL-12/23p40) monoclonal antibody ustekinumab?...

Leggi tutto
Risk of Major Cardiovascular Events in Patients with Psoriasis Receiving Biologic Therapies: a Prospective Cohort Study.

Risk of Major Cardiovascular Events in Patients with Psoriasis Receiving Biologic Therapies: a Prospective Cohort Study.

Ricerca

The cardiovascular safety profile of biologic therapies used for psoriasis is unclear....

Leggi tutto
Psoriasi: grazie alle nuove terapie miglioramenti fino al 90% in poche settimane

Psoriasi: grazie alle nuove terapie miglioramenti fino al 90% in poche settimane

Rassegna stampa

Con l’arrivo dei nuovi farmaci, oggi il trattamento di questa malattia infiammatoria è in grado di restituire ai pazienti una pelle pulita senza effetti collaterali pesanti. Ma è importante fare riferimento al dermatologo per una d...

Leggi tutto
Brodalumab Achieves Superior Lesion Clearance Compared With Secukinumab and Ustekinumab in Moderate-to-Severe Psoriasis

Brodalumab Achieves Superior Lesion Clearance Compared With Secukinumab and Ustekinumab in Moderate-to-Severe Psoriasis

Rassegna stampa

More patients with moderate-to-severe psoriasis achieved "clear" or "almost clear" status with brodalumab than with secukinumab using Psoriasis Area and Severity (PASI) scores...

Leggi tutto
Switching to Brodalumab From Ustekinumab Improves Clearance in Moderate-to-Severe Psoriasis

Switching to Brodalumab From Ustekinumab Improves Clearance in Moderate-to-Severe Psoriasis

Rassegna stampa

Patients with moderate-to-severe psoriasis that did not adequately respond to ustekinumab achieve high levels of lesion clearance after switching to brodalumab rescue therapy...

Leggi tutto
Ixekizumab Superior to Ustekinumab for Treating Psoriasis

Ixekizumab Superior to Ustekinumab for Treating Psoriasis

Rassegna stampa

Patients with psoriasis treated with the targeted agent ixekizumab appear to have better outcomes at 24 weeks than those treated with ustekinumab, according to the 24-week data of the ongoing IXORA-S trial presented at the 2017 Annual ...

Leggi tutto
Psoriasi, farmaci biologici a tutti i malati?

Psoriasi, farmaci biologici a tutti i malati?

Rassegna stampa

Se somministrare o meno i nuovi farmaci biologici a tutti i malati di psoriasi è la domanda che ha «tenuto banco» al congresso annuale dell'Accademia Europea di Dermatologia (EADV) che si è da poco concluso a Vienna....

Leggi tutto
Ustekinumab Effective in Treatment of Psoriatic Arthritis With Spondylitis

Ustekinumab Effective in Treatment of Psoriatic Arthritis With Spondylitis

Rassegna stampa

Ustekinumab, an anti-interleukin (IL)-12 and IL-23 antibody approved for the treatment of psoriatic arthritis, shows significant improvement in patients with psoriatric arthritis who also have spondylitis and peripheral joint involveme...

Leggi tutto